Mexico: Recent Developments In Clinical Data Exclusivity

Evolution of data exclusivity

Mexico, along with the United States and Canada, was one of the first countries to sign data protection provisions in a free trade agreement. The North American Free Trade Agreement (NAFTA) included obligations related to the protection of data submitted before regulatory agencies well before the Agreement on Trade-Related Aspects of IP Rights (TRIPs).

Paragraphs 5 to 7 of Article 1711 of NAFTA contain specific provisions with regard to data submitted to entities in charge of granting market approvals for pharmaceutical and agrochemical products, with the main obligation imposed on the contracting states to prevent unfair commercial use of such information. NAFTA has always been considered a more specific standard for the protection of clinical data than TRIPs, as it provides for a minimum standard of five years of protection from the date that market authorisation was granted.

However, such paragraphs are not as clear as intended, allowing compliance with the treaty by simply keeping the information confidential. Mexico has enacted no specific national provisions that could facilitate the interpretation or implementation of the treaty. The only reference to the treaty is included in the Industrial Property Law, which states in Article 86bis that any information required for determining safety and efficacy of pharmaceutical and agrochemical products using novel chemical compounds will be protected under the terms of the international treaties to which Mexico is party.

For many years, the results of clinical trials submitted to the health authorities were not published or otherwise made available to the public. The government argued that this was in compliance with the treaties because the information collected was kept confidential. In fact, not a single case of grant of a generic drug approval (before the five¬year period mentioned in TRIPs and NAFTA) had been documented, perhaps because of the existence of patents covering longer periods.

Accordingly, data exclusivity enforcement in Mexico was theoretically difficult because not all drugs commercialised after a first approval required bioequivalence tests – that is, the so¬called ‘lookalikes’. Mexico was technically not obliged to prevent unfair commercial use because the information for the drug that had been approved first was not publicly available from the Federal Commission for the Protection against Sanitary Risk and therefore not ‘used’ by generic manufacturers.

Since February 2008, modifications to the Health Supplies Regulations have led to the elimination of lookalikes and interchangeable generics, for which registration was based on general public data, by providing for only two kinds of drug:

  • innovator drugs, based on information from clinical trials; and
  • generic drugs, based on bioequivalence tests without the need for full clinical trials.

Although growing concerns regarding the quality of lookalikes drove these changes, inadvertently they also made applicable one of the specific rules under NAFTA for the fiveyear protection term.

NAFTA provides for the data exclusivity of bioequivalence testing because the grant of generic drugs based on such testing is expressly included as possible if the fiveyear protection term is granted. However, the enactment of specific laws supporting such interpretation was still missing, as there were no court or administrative precedents that could support such an interpretation.

In practice, there were still no cases of grants of generic drug approvals within five years of the date of first registration of a drug in Mexico, although there have been attempts that are still under litigation. However, under new definitions incorporated into Mexican law, ‘innovator medicaments’ were defined as medicaments using or constituting new molecules, combinations of drugs that were not used formerly in Mexico, new indications or new formulations – all of which required the generation of clinical data and therefore, in principle, were protected by NAFTA.

The law further included the enactment of provisions related to biotechnology drugs and biocomparable (biosimilar) drugs. However, no provisions were raised regarding the possibility of a higher term of protection for such drugs.

Congress made some effort to compile an amendment regulating NAFTA and TRIPs obligations in the General Law on Health by considering a longer term of between 8 and 12 years for biotechnology drugs. Under the provisions related to such drugs, biotechnology drugs were considered simply as traditional chemical drugs with no differentiated treatment. With the recent change in government, the negotiations on such an amendment to the law were halted.

However, as the G20 forum was held in Mexico in June 2012 and Mexico wanted to enter negotiations for the TransPacific Strategic Economic Partnership Agreement, the government was urged to deal with three important pending IP issues:

  • the Madrid Protocol;
  • the Anticounterfeiting Trade Agreement; and
  • data exclusivity for pharmaceutical products.

In terms of data exclusivity for pharmaceutical products in particular, as the obligation of international treaties is imposed on contracting states, the government decided to enact such provisions through a set of internal rules that are mandatory only for officers of the Federal Commission for the Protection against Sanitary Risk.

New rules

The Guidelines for the Protection of Confidential Information of Medicines containing Pharmochemicals as a New Chemical Entity were published on June 18 2012. The Federal Commission for the Protection against Sanitary Risk expressly stated that the confidential information received in conjunction with a health approval application is subject to protection against unfair commercial use and public disclosure according to NAFTA and TRIPs. Such information is subject to a fiveyear term of data protection in Mexico from the date that approval is granted.

As already mentioned, as a matter of law, these guidelines are mandatory only for officers of the Federal Commission for the Protection against Sanitary Risk, but are not necessarily applicable in general to applicants applying for either new drugs or generic drug approvals, since they have only internal effects.

The guidelines expressly refer to Article 167 of the Health Supplies Regulations, which relates to data subject to protection according to international treaties. This article in turn describes the requirement to submit scientifically evidenced safety and efficacy data, which is therefore now recognised as subject to protection under the treaties for the first time in Mexico since NAFTA was signed.

On the other hand, the guidelines place a burden on the data owner of determinations that correspond to the Federal Commission for the Protection against Sanitary Risk. For example, the guidelines state that protection will be granted if the applicant proves that the submitted data relates to pharmochemical products that:

  • use “new chemical components”;
  • are related to safety and efficacy under the Health Supplies Regulations;
  • remain unpublished or were published in order to protect the public;
  • were protected against unfair commercial use by certain measures; and
  • the data for which was obtained through considerable effort.

It seems that the rules intended for internal officers of the Federal Commission for the Protection against Sanitary Risk place a burden on the applicant of a sanitary registration of a new drug, since on the one hand, officers must evaluate the submitted data, but on the other hand, submission of such data by the applicant of a new drug approval is not mandatory.

For biocomparable drugs, the guidelines refer only to Article 167 of the Health Supplies Regulations, without mentioning Article 177, which refers to data requested for the approval of biotechnology medicaments.

The drafting of the rules in the form of guidelines seems to have the intention of specifically excluding data related to formulations or new indications and also all data related to biocomparable drugs. The omission of Article 177 and the emphasis on the terms ‘new chemical component’ and ‘new chemical entity’ in the guidelines seem to support such an approach by the Federal Commission for the Protection against Sanitary Risk.

However, due to the different definitions used in the guidelines and the lack of consistency resulting from the use of terms that were not defined under applicable Mexican law, other interpretations seem possible and the final effect is yet to be determined.

One such inconsistency relates to Articles 166(III) and 2 of the Health Supplies Regulations. Under this law, medicaments for which safety and efficacy must be demonstrated based on information from clinical trials are those containing ‘new molecules’. The term, as mentioned above, comprises new molecular entities, but also drugs or combinations of drugs that were not used previously in Mexico, new indications or new formulations. Therefore, it might be possible to interpret that the terms ‘new chemical component’ and ‘new chemical entity’ are synonymous with the term ‘new molecule’, as this is the only term defined as such in Mexican law. However, this is not a straightforward issue.

The guidelines further fail to clarify the scope and nature of the protection resulting from a mix of language and concepts that are inconsistent with Mexican law ¬ for example, use of the terms ‘pharmochemical products’, ‘pharmochemical medicines’ and ‘new chemical components’ instead of the clearly defined term contained in Article 221 of the Law on Health: ‘medicament’.

The terms ‘pharmochemical products’ and ‘pharmochemical medicines’ are groundless, since they are undefined within the law; therefore, it is open to debate whether the regulations are illegal, since they contemplate terms that are not established in Mexican law, TRIPs or NAFTA. Likewise, the term ‘new chemical component’ is used indistinctly with the term ‘new chemical entity’, instead of ‘new molecule’ – a term also expressly defined in the Law on Health. This situation has led to discussions regarding the real intention of the guidelines when these different terms were cited.

What to expect

As explained above, the rules do not seem to clarify and implement in full the scope of NAFTA or TRIPs provisions. Instead, the new guidelines generate uncertainties that formerly did not exist, such as the term for biotechnology drugs (if any) and the applicability of the protection to data other than for new chemical components.

Therefore, there is still the need for a specific amendment that can consider all of the aspects of an efficient implementation of both treaties (ie, NAFTA and TRIPs), perhaps through amendments which align the guidelines with Mexican law by enacting a specific law regarding compliance with the treaties. Such an amendment must be executed directly into the law, or at least into the regulations, but not simply through internal regulations that are applicable only to the Federal Commission for the Protection against Sanitary Risk (as occurred with these new rules); otherwise, the nature and legality of the disposition that contemplates the date exclusivity provisions will always be a point of debate.

As the guidelines are implemented and used by officers of the Federal Commission for the Protection against Sanitary Risk in their decisions, litigation from generic manufacturers and affected data owners may arise which challenge the regulations per se or also challenge decisions issued by the commission grounded on this guidelines, under the main argument that internal dispositions cannot be applied to the general public.

In addition, it is also probable that the application of these guidelines will result in litigation claiming lack of clarity in the scope of the guidelines and in the language and wording of the provisions. Litigation might arise from both innovators and generics, depending on the way that the commission interprets the provisions. This seems to be the most likely scenario, considering that with the change of government in Mexico, the passing of the law that is still pending in Congress seems unlikely.

However, as TransPacific Strategic Economic Partnership Agreement negotiations progress and the obligations related to IP enforcement and compliance advance, we may also see some willingness from the government towards more specific implementation, with the main aim being a clear position regarding biotechnology drugs.

The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.

To print this article, all you need is to be registered on Mondaq.com.

Click to Login as an existing user or Register so you can print this article.

Authors
Héctor Chagoya
 
Some comments from our readers…
“The articles are extremely timely and highly applicable”
“I often find critical information not available elsewhere”
“As in-house counsel, Mondaq’s service is of great value”

Up-coming Events Search
Tools
Print
Font Size:
Translation
Channels
Mondaq on Twitter
 
Register for Access and our Free Biweekly Alert for
This service is completely free. Access 250,000 archived articles from 100+ countries and get a personalised email twice a week covering developments (and yes, our lawyers like to think you’ve read our Disclaimer).
 
Email Address
Company Name
Password
Confirm Password
Position
Mondaq Topics -- Select your Interests
 Accounting
 Anti-trust
 Commercial
 Compliance
 Consumer
 Criminal
 Employment
 Energy
 Environment
 Family
 Finance
 Government
 Healthcare
 Immigration
 Insolvency
 Insurance
 International
 IP
 Law Performance
 Law Practice
 Litigation
 Media & IT
 Privacy
 Real Estate
 Strategy
 Tax
 Technology
 Transport
 Wealth Mgt
Regions
Africa
Asia
Asia Pacific
Australasia
Canada
Caribbean
Europe
European Union
Latin America
Middle East
U.K.
United States
Worldwide Updates
Check to state you have read and
agree to our Terms and Conditions

Terms & Conditions and Privacy Statement

Mondaq.com (the Website) is owned and managed by Mondaq Ltd and as a user you are granted a non-exclusive, revocable license to access the Website under its terms and conditions of use. Your use of the Website constitutes your agreement to the following terms and conditions of use. Mondaq Ltd may terminate your use of the Website if you are in breach of these terms and conditions or if Mondaq Ltd decides to terminate your license of use for whatever reason.

Use of www.mondaq.com

You may use the Website but are required to register as a user if you wish to read the full text of the content and articles available (the Content). You may not modify, publish, transmit, transfer or sell, reproduce, create derivative works from, distribute, perform, link, display, or in any way exploit any of the Content, in whole or in part, except as expressly permitted in these terms & conditions or with the prior written consent of Mondaq Ltd. You may not use electronic or other means to extract details or information about Mondaq.com’s content, users or contributors in order to offer them any services or products which compete directly or indirectly with Mondaq Ltd’s services and products.

Disclaimer

Mondaq Ltd and/or its respective suppliers make no representations about the suitability of the information contained in the documents and related graphics published on this server for any purpose. All such documents and related graphics are provided "as is" without warranty of any kind. Mondaq Ltd and/or its respective suppliers hereby disclaim all warranties and conditions with regard to this information, including all implied warranties and conditions of merchantability, fitness for a particular purpose, title and non-infringement. In no event shall Mondaq Ltd and/or its respective suppliers be liable for any special, indirect or consequential damages or any damages whatsoever resulting from loss of use, data or profits, whether in an action of contract, negligence or other tortious action, arising out of or in connection with the use or performance of information available from this server.

The documents and related graphics published on this server could include technical inaccuracies or typographical errors. Changes are periodically added to the information herein. Mondaq Ltd and/or its respective suppliers may make improvements and/or changes in the product(s) and/or the program(s) described herein at any time.

Registration

Mondaq Ltd requires you to register and provide information that personally identifies you, including what sort of information you are interested in, for three primary purposes:

  • To allow you to personalize the Mondaq websites you are visiting.
  • To enable features such as password reminder, newsletter alerts, email a colleague, and linking from Mondaq (and its affiliate sites) to your website.
  • To produce demographic feedback for our information providers who provide information free for your use.

Mondaq (and its affiliate sites) do not sell or provide your details to third parties other than information providers. The reason we provide our information providers with this information is so that they can measure the response their articles are receiving and provide you with information about their products and services.

If you do not want us to provide your name and email address you may opt out by clicking here .

If you do not wish to receive any future announcements of products and services offered by Mondaq by clicking here .

Information Collection and Use

We require site users to register with Mondaq (and its affiliate sites) to view the free information on the site. We also collect information from our users at several different points on the websites: this is so that we can customise the sites according to individual usage, provide 'session-aware' functionality, and ensure that content is acquired and developed appropriately. This gives us an overall picture of our user profiles, which in turn shows to our Editorial Contributors the type of person they are reaching by posting articles on Mondaq (and its affiliate sites) – meaning more free content for registered users.

We are only able to provide the material on the Mondaq (and its affiliate sites) site free to site visitors because we can pass on information about the pages that users are viewing and the personal information users provide to us (e.g. email addresses) to reputable contributing firms such as law firms who author those pages. We do not sell or rent information to anyone else other than the authors of those pages, who may change from time to time. Should you wish us not to disclose your details to any of these parties, please tick the box above or tick the box marked "Opt out of Registration Information Disclosure" on the Your Profile page. We and our author organisations may only contact you via email or other means if you allow us to do so. Users can opt out of contact when they register on the site, or send an email to unsubscribe@mondaq.com with “no disclosure” in the subject heading

Mondaq News Alerts

In order to receive Mondaq News Alerts, users have to complete a separate registration form. This is a personalised service where users choose regions and topics of interest and we send it only to those users who have requested it. Users can stop receiving these Alerts by going to the Mondaq News Alerts page and deselecting all interest areas. In the same way users can amend their personal preferences to add or remove subject areas.

Cookies

A cookie is a small text file written to a user’s hard drive that contains an identifying user number. The cookies do not contain any personal information about users. We use the cookie so users do not have to log in every time they use the service and the cookie will automatically expire if you do not visit the Mondaq website (or its affiliate sites) for 12 months. We also use the cookie to personalise a user's experience of the site (for example to show information specific to a user's region). As the Mondaq sites are fully personalised and cookies are essential to its core technology the site will function unpredictably with browsers that do not support cookies - or where cookies are disabled (in these circumstances we advise you to attempt to locate the information you require elsewhere on the web). However if you are concerned about the presence of a Mondaq cookie on your machine you can also choose to expire the cookie immediately (remove it) by selecting the 'Log Off' menu option as the last thing you do when you use the site.

Some of our business partners may use cookies on our site (for example, advertisers). However, we have no access to or control over these cookies and we are not aware of any at present that do so.

Log Files

We use IP addresses to analyse trends, administer the site, track movement, and gather broad demographic information for aggregate use. IP addresses are not linked to personally identifiable information.

Links

This web site contains links to other sites. Please be aware that Mondaq (or its affiliate sites) are not responsible for the privacy practices of such other sites. We encourage our users to be aware when they leave our site and to read the privacy statements of these third party sites. This privacy statement applies solely to information collected by this Web site.

Surveys & Contests

From time-to-time our site requests information from users via surveys or contests. Participation in these surveys or contests is completely voluntary and the user therefore has a choice whether or not to disclose any information requested. Information requested may include contact information (such as name and delivery address), and demographic information (such as postcode, age level). Contact information will be used to notify the winners and award prizes. Survey information will be used for purposes of monitoring or improving the functionality of the site.

Mail-A-Friend

If a user elects to use our referral service for informing a friend about our site, we ask them for the friend’s name and email address. Mondaq stores this information and may contact the friend to invite them to register with Mondaq, but they will not be contacted more than once. The friend may contact Mondaq to request the removal of this information from our database.

Security

This website takes every reasonable precaution to protect our users’ information. When users submit sensitive information via the website, your information is protected using firewalls and other security technology. If you have any questions about the security at our website, you can send an email to webmaster@mondaq.com.

Correcting/Updating Personal Information

If a user’s personally identifiable information changes (such as postcode), or if a user no longer desires our service, we will endeavour to provide a way to correct, update or remove that user’s personal data provided to us. This can usually be done at the “Your Profile” page or by sending an email to EditorialAdvisor@mondaq.com.

Notification of Changes

If we decide to change our Terms & Conditions or Privacy Policy, we will post those changes on our site so our users are always aware of what information we collect, how we use it, and under what circumstances, if any, we disclose it. If at any point we decide to use personally identifiable information in a manner different from that stated at the time it was collected, we will notify users by way of an email. Users will have a choice as to whether or not we use their information in this different manner. We will use information in accordance with the privacy policy under which the information was collected.

How to contact Mondaq

You can contact us with comments or queries at enquiries@mondaq.com.

If for some reason you believe Mondaq Ltd. has not adhered to these principles, please notify us by e-mail at problems@mondaq.com and we will use commercially reasonable efforts to determine and correct the problem promptly.